Favipiravir (T-705), a novel viral RNA polymerase inhibitor
Top Cited Papers
- 1 November 2013
- journal article
- review article
- Published by Elsevier BV in Antiviral Research
- Vol. 100 (2), 446-454
- https://doi.org/10.1016/j.antiviral.2013.09.015
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (NIH) (HHSN272201000039I)
- NIH
This publication has 30 references indexed in Scilit:
- Combinations of favipiravir and peramivir for the treatment of pandemic influenza A/California/04/2009 (H1N1) virus infections in miceAntiviral Research, 2012
- T-705 (Favipiravir) Inhibition of Arenavirus Replication in Cell CultureAntimicrobial Agents and Chemotherapy, 2011
- Efficacy of favipiravir (T-705) and T-1106 pyrazine derivatives in phlebovirus disease modelsAntiviral Research, 2010
- T-705 (favipiravir) activity against lethal H5N1 influenza A virusesProceedings of the National Academy of Sciences of the United States of America, 2009
- Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cellsJournal of Antimicrobial Chemotherapy, 2009
- In vitro and in vivo characterization of new swine-origin H1N1 influenza virusesNature, 2009
- Effect of T-705 treatment on western equine encephalitis in a mouse modelAntiviral Research, 2009
- Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodentsAntiviral Research, 2008
- Surveillance for Neuraminidase Inhibitor Resistance among Human Influenza A and B Viruses Circulating Worldwide from 2004 to 2008Antimicrobial Agents and Chemotherapy, 2008
- In Vitro and In Vivo Activities of T-705 against Arenavirus and Bunyavirus InfectionsAntimicrobial Agents and Chemotherapy, 2007